Saw where a rep reposted CM227 story on linkedin, what a dumbass. Should be an opening in that territory soon.
Yes seeing how neither drug is approved in 1L NSCLC, I'd say that was not very smart AC. You should go ahead and inform your manager right away. .... Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)
All I can say is that the stocks of BMS and Merck have moved in the opposite directions since the trial news came out.
BMS takeover rumors have been out there as long as one can remember. This may have gained momentum based on positive 227 study related news. Curiously though, Merck stock has declined after this news broke.